PFM
AGRX

Parsec Financial Management’s Agile Therapeutics AGRX Stock Holding History

Parsec Financial Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41
Closed -$17K – 307
2022
Q1 		$17K Buy
41
+35
+583% +$22.3K ﹤0.01% 300
2021
Q4 		$5K Hold
6
– – ﹤0.01% 290
2021
Q3 		$8K Buy
+6
New +$13.6K ﹤0.01% 281

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parsec Financial Management's AGRX Position: Q2 2022 in Review

Parsec Financial Management sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 41 shares — an estimated $17K sold.

Parsec Financial Management first reported a position in AGRX in Q3 2021 and held it in 3 quarters. The position peaked at $17K in Q1 2022. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

  • Parsec Financial Management reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Parsec Financial Management sold 41 Agile Therapeutics shares in Q2 2022, an estimated $17K.
  • Parsec Financial Management first reported a position in Agile Therapeutics in Q3 2021 and held it in 3 quarters.
  • Parsec Financial Management's Agile Therapeutics position peaked at $17K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on Parsec Financial Management's 13F filing for Q2 2022, filed 6 Jul 2022.